Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$72.07 USD
-1.24 (-1.69%)
Updated Sep 19, 2025 11:21 AM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZLDPF 72.07 -1.24(-1.69%)
Will ZLDPF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
Other News for ZLDPF
M&A News: 89bio Stock (ETNB) Jumps 83% on $3.5B Acquisition by Roche
J.P. Morgan Reaffirms Their Buy Rating on Zealand Pharma (ZLDPF)
SA Asks: Which biotechs could be acquired by year's end?
Metsera: An Emerging Contender In The GLP???1 Arena
Zealand Pharma A/S (ZLDPF) Presents at Cantor Global Healthcare Conference 2025 Transcript